2017 Fiscal Year Final Research Report
Clinical trial of peptide vaccination with oral chemotherapy following curative resection for stage III colorectal cancer
| Project/Area Number |
15K10153
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Kindai University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
杉浦 史哲 近畿大学, 医学部附属病院, 講師 (10580631)
奥野 清隆 近畿大学, 医学部, 教授 (30169239)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | 大腸癌 / ペプチドワクチン / 術後補助療法 / CTL反応 / 細胞障害性T細胞 |
|---|
| Outline of Final Research Achievements |
We conducted a phase II clinical trial involving patients with stage III CRC. All enrolled patients whose human leukocyte antigen (HLA)-A status was double-blinded were administered the same regime of a peptide vaccine and UFT/LV chemotherapy. The primary objective of the study was the comparison of relapse-free survival (RFS) in patients with HLA-A*2402 versus those without HLA-A*2402. A total of 46 patients were enrolled in the study. Three-year RFS was not significantly different between HLA-A*2402 matched and unmatched groups. Three-year RFS was significantly better in patients with positive CTL responses in the HLA-A*2402 matched group compared with those without. In conclusion, vaccination-induced immune responses combined with UFT/LV are positively associated with survival benefit in patients with HLA-A* 2402-positive stage III CRC.
|
| Free Research Field |
消化器外科
|
